H1B Salary Data

Home › Employers › Med-Pharmex, Inc.

Med-Pharmex, Inc.: H-1B salaries and sponsorship

Med-Pharmex, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $93,142.

Applications (LCAs)3
Certified3
Employer addressPomona, CA
H-1B dependent employerNo
Median offered salary$93,142
Middle half of salaries$85,768–$119,912
10th–90th percentile$81,344–$135,974

Does Med-Pharmex, Inc. sponsor H-1B visas?

Med-Pharmex, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Feb 12, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Pharmaceutical Chemist1$78,395
Pharmaceutical Validation Lead/Director1$146,682
Pharmaceutical Validation Engineer1$93,142

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20232$112,538
FY20251$93,142

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Pharmaceutical Validation Engineer$93,142–$130,000
Level III
Pomona, CAFeb 12, 2025Aug 9, 2025Certified
Pharmaceutical Validation Lead/Director$146,682–$170,000
Level II
Pomona, CAApr 12, 2023Oct 9, 2023Certified
Pharmaceutical Chemist$78,395–$97,000
Level III
Pomona, CAMar 8, 2023Aug 19, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).